2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 291-292
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Gene Therapy, Women’s Health, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Genetic Disorders, Hemoglobinopathies, Thalassemia, Metabolic Disorders, Iron Deficiency, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pregnant, Animal Model
PAPER

858 Early antenatal support for iron deficiency anemia (EASI-A): A randomized controlled trial

Rupsa C Boelig, MD, Fran Dipietro2, Michael Auerbach, MD3, Richard Derman, MD4, Vincenzo Berghella, MD5
1 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
3 Georgetown University, Washington DC, United States
4 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
5 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Background: Most trials comparing IV vs oral iron in pregnancy enroll in 3rd trimester and after oral iron failure. We aimed to determine the benefit of early, initial, use of intravenous compared to oral iron in improving hemoglobin through gestation in patients with iron deficiency anemia.

Objective: Determine whether IV iron is superior to oral iron in improving maternal hemoglobin 90 days post-treatment in pregnancies with iron deficiency anemia (Hb 9.0-10.9) in the second trimester (14 0/7 - 27 6/7 weeks)

Methods: This is a parallel unblinded randomized controlled trial comparing IV ferumoxytol vs oral iron in management of iron deficiency anemia in the second trimester. Inclusion criteria were singleton gestations with iron deficiency anemia diagnosed by Hb 9.0-10.9 AND ferritin <30ng/ml OR total iron saturation<20% at gestational age <28 weeks gestation. Participants were randomized after 14 weeks' gestation to either 1) Intravenous ferumoxtyol 510mg infusion administered twice, 3-8 days apart or 2) oral iron 65mg BID. Standard of care included IV iron infusion if Hb<10.0 in 3rd trimester or >30d after treatment (whichever was later). Primary outcome was change from baseline Hb at 90 days post treatment. Secondary outcomes included achieving anemia resolution (Hb≥11.0g/dL), change in Hb and ferritin at each study visit (30, 60, 90d post treatment and delivery), quality of life measures, and maternal/infant outcomes. Sample size goal was N=80 to account for 20% loss to follow up and estimating a change in baseline of 1.5± 0.75 in the oral iron group and 2.0± 0.75 in the IV iron group. Analysis was intention to treat and reported as mean difference (95% confidence interval)

Results: 80 participants were enrolled, 40 randomized to each group. There were 2 withdrawals in the IV iron group, and 3 withdrawals and 2 losses to follow up in oral iron group. Included in the analysis was N=38 in the IV iron group, with n=2 (5%) cross-over to oral iron; and N=35 in the oral iron group with N=11 (31%) treatment cross-over. Both IV iron cross-over were due to adverse reaction to iron infusion and treatment cessation (recovered immediately with medical management). 10 of 11 oral iron crossovers were due to Hb<10.0 in 3rd trimester, and 1/10 was due to side effects. The study population included 68.5% Black, 6.8% White, 21.9% Hispanic/White, and 2.7% Hispanic/Black. Average gestational age of enrollment was 20.3wk vs 21.7wk in IV vs oral iron (p>0.05).The IV iron group had a lower baseline Hb (9.9 vs 10.3, MD-0.38 (-0.78 to 0, p=0.05), but baseline characteristics were otherwise similar. In unadjusted analysis, there was significantly greater improvement in Hb at 30, 60, 90d, and delivery in IV vs oral iron (MD 1.15 (0.70-1.61), MD 1.50 (0.92-2.08), MD 1.10 (0.47-1.75), MD 0.77 (0.13-1.41). There was a greater likelihood of anemia resolution at 90 days post treatment with IV vs oral iron (79.4% vs 46.9%, RR 1.69 (1.12-2.54)), with a trend of superiority by delivery as well (84.8% vs 64.7% RR 1.31 (0.98-1.75)), likely related to treatment cross-over and rescue IV iron in oral iron group.

Conclusion: A single course of intravenous iron in the second trimester is superior to BID oral iron in improving hemoglobin through gestation/delivery and more rapidly attaining and maintaining resolution of anemia, even with use of rescue IV iron treatment for persistent anemia in the 3rd trimester in the oral iron group. This highlights the difficulty of “catching up” to resolve progressive iron deficiency anemia with advancing gestation after initial treatment with oral iron. Guidelines should address the potential benefit of early 2nd trimester use of intravenous iron as the initial treatment for iron deficiency anemia in pregnancy.

Rupsa C Boelig, MD: COVIS Pharma - Research Funding